Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Sep;68(3):590–593. doi: 10.1038/bjc.1993.391

Depletion of circulating cyst(e)ine by oral and intravenous mesna.

B Stofer-Vogel 1, T Cerny 1, A Küpfer 1, E Junker 1, B H Lauterburg 1
PMCID: PMC1968397  PMID: 8353049

Abstract

The sulfhydryl status of normal and tumour cells is critically important in determining their susceptibility to various cytostatic agents. As a sulfhydryl compound, mesna (sodium 2-mercaptoethane-sulfonate) which is used in large doses to prevent haemorrhagic cystitis associated with certain chemotherapeutic regimens might derange cellular thiol homeostasis. In order to investigate the effects of mesna on the concentrations of thiols in plasma, cysteine, glutathione and their disulfides were measured by HPLC following the oral and intravenous administration of mesna to healthy volunteers. After 7.3 mmol mesna i.v. free cysteine rose from 8.2 (95% CI 7.0-9.4) nmol ml-1 to 53.6 (47.4-59.8) nmol ml-1 at 5 min, most likely due to reduction of circulating cystine by the sulfhydryl drug. This initial rise was followed by a marked decrease of total cyst(e)ine in plasma from 276 (215-337) nmol ml-1 to a nadir of 102 (89-115) nmol ml-1 between 30-120 min after infusion, most likely due to an increased uptake of cysteine into cells and an increased urinary excretion of cyst(e)ine. Qualitatively similar changes were seen after oral mesna. The present data indicate that mesna depletes circulating cyst(e)ine and may thereby markedly alter the sulfhydryl status of cells in vivo although the drug itself is not taken up by most cells.

Full text

PDF
590

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aebi S., Assereto R., Lauterburg B. H. High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. Eur J Clin Invest. 1991 Feb;21(1):103–110. doi: 10.1111/j.1365-2362.1991.tb01366.x. [DOI] [PubMed] [Google Scholar]
  2. Aebi S., Lauterburg B. H. Divergent effects of intravenous GSH and cysteine on renal and hepatic GSH. Am J Physiol. 1992 Aug;263(2 Pt 2):R348–R352. doi: 10.1152/ajpregu.1992.263.2.R348. [DOI] [PubMed] [Google Scholar]
  3. Chasseaud L. F. The role of glutathione and glutathione S-transferases in the metabolism of chemical carcinogens and other electrophilic agents. Adv Cancer Res. 1979;29:175–274. doi: 10.1016/s0065-230x(08)60848-9. [DOI] [PubMed] [Google Scholar]
  4. Dechant K. L., Brogden R. N., Pilkington T., Faulds D. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs. 1991 Sep;42(3):428–467. doi: 10.2165/00003495-199142030-00006. [DOI] [PubMed] [Google Scholar]
  5. Duran M., Aarsen G., Fokkens R. H., Nibbering N. M., Cats B. P., de Bree P. K., Wadman S. K. 2-Mercaptoethanesulfonate-cysteine disulfide excretion following the administration of 2-mercaptoethanesulfonate--a pitfall in the diagnosis of sulfite oxidase deficiency. Clin Chim Acta. 1981 Mar 19;111(1):47–53. doi: 10.1016/0009-8981(81)90419-8. [DOI] [PubMed] [Google Scholar]
  6. Issels R. D., Nagele A., Eckert K. G., Wilmanns W. Promotion of cystine uptake and its utilization for glutathione biosynthesis induced by cysteamine and N-acetylcysteine. Biochem Pharmacol. 1988 Mar 1;37(5):881–888. doi: 10.1016/0006-2952(88)90176-1. [DOI] [PubMed] [Google Scholar]
  7. James C. A., Mant T. G., Rogers H. J. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. Br J Clin Pharmacol. 1987 May;23(5):561–568. doi: 10.1111/j.1365-2125.1987.tb03092.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jones M. S., Murrell R. D., Shaw I. C. Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing. Eur J Cancer Clin Oncol. 1985 May;21(5):553–555. doi: 10.1016/0277-5379(85)90079-3. [DOI] [PubMed] [Google Scholar]
  9. Lauterburg B. H., Davies S., Mitchell J. R. Ethanol suppresses hepatic glutathione synthesis in rats in vivo. J Pharmacol Exp Ther. 1984 Jul;230(1):7–11. [PubMed] [Google Scholar]
  10. McGown A. T., Fox B. W. A proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in a Yoshida cell line in vitro. Cancer Chemother Pharmacol. 1986;17(3):223–226. doi: 10.1007/BF00256688. [DOI] [PubMed] [Google Scholar]
  11. Ormstad K., Orrenius S., Låstbom T., Uehara N., Pohl J., Stekar J., Brock N. Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat. Cancer Res. 1983 Jan;43(1):333–338. [PubMed] [Google Scholar]
  12. Shaw I. C., Weeks M. S. Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing. Eur J Cancer Clin Oncol. 1987 Jul;23(7):933–935. doi: 10.1016/0277-5379(87)90338-5. [DOI] [PubMed] [Google Scholar]
  13. Stofer-Vogel B., Cerny T., Borner M., Lauterburg B. H. Oral bioavailability of mesna tablets. Cancer Chemother Pharmacol. 1993;32(1):78–81. doi: 10.1007/BF00685881. [DOI] [PubMed] [Google Scholar]
  14. de Quay B., Malinverni R., Lauterburg B. H. Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral N-acetylcysteine. AIDS. 1992 Aug;6(8):815–819. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES